Heads Up! Migraine Drug Ads Soon May Give Millions Headaches! | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Four major pharmaceutical companies are in a race to be the first to offer a drug that may rapidly reduce—and even prevent—migraines to the more than 38 million Americans affected by the debilitating illness each year.

Alder Biopharmaceuticals, Eli Lilly, Amgen and Teva Pharmaceutical have all developed migraine drugs which have completed or are currently undergoing Phase 3 clinical trials using a compound called calcitonin gene-related peptide (or CGRP) that contains antibodies that attack the protein in the brain that causes the severe headaches.

“All four anti-CGRP trials currently underway by the separate companies are positive, showing very promising efficacy for patients and good safety profiles so far. In terms of timing, Amgen’s drug is currently on track to be the first available to patients,” Carl Cincinnato, director of Quantified Health and The Migraine World Summit, told FOX Business.

According to the Migraine Research Foundation, the illness is the 3rd most prevalent—and the 6th most disabling—in the world and affects 12% of the U.S. population, including children. Women and children are impacted the most at 18% and 10%, respectively, while men make up just 6% of the population.